OphthalmologyNews.net

Ophthalmology Xagena

XagenaNewsletter
Xagena Mappa
Medical Meeting
Reumabase.it

Primary open-angle glaucoma linked to increased risk of chronic kidney disease


The association between primary open-angle glaucoma ( POAG ) and subsequent development of chronic kidney disease ( CKD ) was investigated using a nationwide, population-based, retrospective cohort in South Korea.
Primary open-angle glaucoma increases the risk of subsequent CKD development.

The purpose of this study was to investigate the risk of subsequent CKD development in patients with primary open-angle glaucoma.

In this nationwide, population-based longitudinal cohort, 1,025,340 beneficiaries in the 2002-2013 Korean National Health Insurance database were included.
Investigators identified patients with incident primary open-angle glaucoma and evaluated the risk of subsequent CKD development using diagnostic codes from the database after 2-year wash-out periods.
They applied time-varying covariate Cox regression analyses to determine the effect of POAG on the development of chronic kidney disease: Model 1 included only primary open-angle glaucoma as a time-varying covariate; Model 2 included Model 1 and demographic information; and Model 3 included Model 2, comorbidity, comedication, and the Charlson Comorbidity Index score.

The fixed cohort included 478,303 eligible subjects, and of these subjects, 1749 suffered incident primary open-angle glaucoma, and 3157 developed chronic kidney disease.

Primary open-angle glaucoma was associated with an increased risk of CKD development [ hazard ratio, HR=7.63; 95% confidence interval ( CI ), 5.89-9.87 ] in Model 1; HR=3.54 ( 95% CI, 2.73-4.58 ) in Model 2; and HR=2.90 ( 95% CI, 2.24-3.76 ) in Model 3 ].

In conclusion, primary open-angle glaucoma increased the risk of subsequent chronic kidney disease in the general population, suggesting that primary open-angle glaucoma and chronic kidney disease might share a common pathogenic mechanism. ( Xagena )

Park SJ et al, Journal of Glaucoma 2019; 28: 1067-1073

XagenaMedicine_2019



Indietro